摘要: Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation glucagon-like peptide 1 (GLP-1), which increases levels active GLP-1. This insulin secretion and reduces glucagon secretion, thereby lowering glucose levels. Several inhibitors are in clinical development. Most experience so far has been with sitagliptin (Merck; approved by FDA) vildagliptin (Novartis; filed). These orally compounds long duration, allowing once-daily administration. Both improve metabolic control diabetes, both monotherapy combination metformin thiazolidinediones. A reduction HbA(1c) approximately 1% seen studies up to 52 weeks' duration. safe well tolerated, risk hypoglycaemia minimal, body-weight neutral. suggested be first-line particularly its early stages metformin. However, durability long-term safety remain established.
elsevier.com
bprcem.com 
core.ac.uk 参考文章(71)
Rolf Mentlein, Cell-Surface Peptidases∗ International Review of Cytology-a Survey of Cell Biology. ,vol. 235, pp. 165- 213 ,(2004) , 10.1016/S0074-7696(04)35004-7
R. Scott, M. Wu, M. Sanchez, P. Stein, Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice. ,vol. 61, pp. 171- 180 ,(2006) , 10.1111/J.1742-1241.2006.01246.X
Lazaros A. Nikolaidis, Sunil Mankad, George G. Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P. Shannon, Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion Circulation. ,vol. 109, pp. 962- 965 ,(2004) , 10.1161/01.CIR.0000120505.91348.58
T. Vilsbøll, J. J. Holst, Incretins, insulin secretion and Type 2 diabetes mellitus Diabetologia. ,vol. 47, pp. 357- 366 ,(2004) , 10.1007/S00125-004-1342-6
V. Fonseca, A. Schweizer, D. Albrecht, M. A. Baron, I. Chang, S. Dejager, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Diabetologia. ,vol. 50, pp. 1148- 1155 ,(2007) , 10.1007/S00125-007-0633-0
Bogdan Balas, Muhammad R Baig, Catherine Watson, Beth E Dunning, Monica Ligueros-Saylan, Yibin Wang, Yan-Ling He, Celia Darland, Jens J Holst, Carolyn F Deacon, Kenneth Cusi, Andrea Mari, James E Foley, Ralph A DeFronzo, None, The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients The Journal of Clinical Endocrinology and Metabolism. ,vol. 92, pp. 1249- 1255 ,(2007) , 10.1210/JC.2006-1882
C. F. Deacon, Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research. ,vol. 36, pp. 761- 765 ,(2004) , 10.1055/S-2004-826160
Y HE, A BALCH, J CAMPESTRINI, G RIVERE, D SERRA, P PRASAD, M LIGUEROSSAYLAN, Pharmacokinetics and pharmacodynamics of the DPP‐4 inhibitor, LAF237, in patients with type 2 diabetes Clinical Pharmacology & Therapeutics. ,vol. 77, ,(2005) , 10.1016/J.CLPT.2004.12.104
Emanuele Bosi, Riccardo Paolo Camisasca, Carole Collober, Erika Rochotte, Alan J Garber, Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Diabetes Care. ,vol. 30, pp. 890- 895 ,(2007) , 10.2337/DC06-1732
Carolyn F. Deacon, What do we know about the secretion and degradation of incretin hormones Regulatory Peptides. ,vol. 128, pp. 117- 124 ,(2005) , 10.1016/J.REGPEP.2004.06.007